5-Aminolevulinic Acid—A Biomarker for Worse Prognosis in IDH-Wildtype II Tumors? Evolution of a Fluorescence-Positive Diffuse Astrocytoma: A Case Report

Introduction  In 2017, the U.S. Food and Drug Administration (FDA) approved 5-aminolevulinic acid (5-ALA) as an intraoperative optical imaging agent in patients with suspected high-grade gliomas (HGGs). However, the application of 5-ALA for low-grade gliomas is still less accepted. Astrocytoma, isoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Valerio, Jose E., Ochoa, Sebastian, Alvarez, Sandra, Borro, Matteo, Alvarez-Pinzon, Andres M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411034/
https://www.ncbi.nlm.nih.gov/pubmed/36032798
http://dx.doi.org/10.1055/a-1858-7628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411034/
https://www.ncbi.nlm.nih.gov/pubmed/36032798
http://dx.doi.org/10.1055/a-1858-7628

Ejemplares similares